On this page, you will find interesting information about the ESR, including facts & figures, details about the executive council, our guiding principles, and much more. Discover everything there is to know about the ESR.

You’re interested in learning more about an ESR membership? Well, you’ve come to the right page. Here, you can discover everything about our memberships, including the benefits and prices. We are sure that you’ll find the perfect option for you.

Part of our mission statement is “Advancing you,” and on this page, you’ll find all of our educational programmes, courses, eBooks, partner links, and downloads, etc., designed to enhance your knowledge and advance your career.

Visit this page for more information about our journals: European Radiology, Insights into Imaging, and European Radiology Experimental, as well as information about Eurorad. Additionally, if you’re interested in publishing your own work, you can find details here.

On this page, patients can find crucial information for their journey towards health, as the European Society of Radiology is at the forefront of advancing patient care and ensuring that individuals receive the assistance they need.

Discover information about our research endeavors and how EIBIR is shaping the future of radiology. Additionally, you’ll find news about research grants, statistics, and details about EIBALL and our Biomarker Inventory.

This is the page for all things ECR and our other events. Learn everything about how to register, submit abstracts, attend in person, become an exhibitor, and much more. There is no congress like ECR. Start your journey here.

Learn more about how the ESR is advancing quality and safety standards in radiology, and access all the information on ESR iGuide, Eurosafe Imaging, our clinical audit tool, as well as ESR-led projects and papers.

Here, you can find information about the ESR’s communal approach to radiology, its relations with EU institutions, international organisations, and other stakeholders, as well as European projects and alliances.

Get in touch →

Membership

Biomarkers Ovary

The following list has been reviewed and approved by the European Society of Urogenital Radiology’s (ESUR)’s Women’s Pelvic Imaging Group.

OVARY

Technique

Level of
evidence1!

Single centre/
Multicentre/
metaanalysis

Indication

Patient prep

Data acquisition
requirements

Image processing
algorithm

Recommended
biomarkers/
primary end-point

RECIST 1.1 combined with CA 125

 

 

511!

Consensus

Response to systemic treatment

No

CE-CT

Manual documentation by trained observer

Recommended biomarkers/
secondary end-point

Morphology (solid-cystic mass, papillary projections, etc.)

12-3!

Multicentre-IOTA

Differentiate benign from malignant

IM antiperistaltic agent

High resolution T2, standard T1 and T1 FS, T1 FS with gadolinium

Manual documentation by trained observer

Dynamic contrast uptake pattern

34-7!

Single centre

Differentiate benign from malignant

IM anitperistaltic agent

Temporal resolution < 15 sec

Construction of time-intensity-curves comparing

DWI (visual)

38!

Single centre

Diagnosis and staging

1L pineapple juice
IM antiperistaltic agent

At least 2 b-values (b=0-50 and b=800-1000 s/mm2)

Manual documentation by trained observer

Multiparametric model
(ADNEXMRscore)

19-10!

Single centre

Differentiate benign from malignant

IM antiperistaltic agent

Conventional MRI + DWI + DCE

Visual interpretation of mass characteristics and TICs
             

Biomarkers in development/
exploratory/ not
recommended

ADC

112-13!

Single centre

Differentiate benign from malignant, histopathological tumour features

IM antiperistaltic agent

At least 2 b-values (b=0-50 and b=800-1000 s/mm2)

Considerable overlap8

ADC histogram analysis

114!

Single centre

Response to systemic treatment

IM antiperistaltic agent

At least 2 b-values (b=0-50 and b=800-1000 s/mm2)

First order histogram parameters

Multiparametric MRI (ADC, ve, MRS)

115!

Single centre

Response to systemic treatment

IM anitperistaltic agent

Multiple b-values

Monoexponential data fit, Tofts model

Radiomics (CT)

316!

Single centre

Outcome prediction

No

CE-CT

No consensus available
  1. Schweitzer ME. Evidence level. J Magn Reson Imaging. 2016;43(3):543-543. doi:10.1002/jmri.25187
  2. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group. Ultrasound Obstet Gynecol. 2000;16(5):500-505. doi:10.1046/j.1469-0705.2000.00287.x
  3. Meys EMJ, Kaijser J, Kruitwagen RFPM, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2016;58:17-29. doi:10.1016/j.ejca.2016.01.007
  4. Bernardin L, Dilks P, Liyanage S, Miquel ME, Sahdev A, Rockall A. Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol. 2012;22(4):880-890. doi:10.1007/s00330-011-2331-z
  5. Thomassin-Naggara I, Bazot M, Daraï E, Callard P, Thomassin J, Cuenod CA. Epithelial Ovarian Tumors: Value of Dynamic Contrast-enhanced MR Imaging and Correlation with Tumor Angiogenesis. Radiology. 2008;248(1):148-159. doi:10.1148/radiol.2481071120
  6. Thomassin-Naggara I, Balvay D, Aubert E, Daraï E, Rouzier R, Cuenod CA, Bazot M. Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study. Eur Radiol. 2012 Apr;22(4):738-45. doi: 10.1007/s00330-011-2329-6. Epub 2011 Nov 23. PubMed PMID: 22105841.
  7. Thomassin-Naggara I, Soualhi N, Balvay D, Darai E, Cuenod CA. Quantifying tumor vascular heterogeneity with DCE-MRI in complex adnexal masses: A preliminary study. J Magn Reson Imaging. 2017 Dec;46(6):1776-1785. doi: 10.1002/jmri.25707. Epub 2017 Apr 3. PubMed PMID: 28370815.
  8. Thomassin-Naggara I, Toussaint I, Perrot N, et al. Characterization of Complex Adnexal Masses: Value of Adding Perfusion- and Diffusion-weighted MR Imaging to Conventional MR Imaging. Radiology. 2011;258(3):793-803. doi:10.1148/radiol.10100751
  9. Thomassin-Naggara I, Aubert E, Rockall A, et al. Adnexal Masses: Development and Preliminary Validation of an MR Imaging Scoring System. Radiology. 2013;267(2):432-443. doi:10.1148/radiol.13121161
  10. Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, Guerra A, Fournier LS, Stojanovic S, Millet I, Bharwani N, Juhan V, Cunha TM, Masselli G, Balleyguier C, Malhaire C, Perrot NF, Sadowski EA, Bazot M, Taourel P, Porcher R, Darai E, Reinhold C, Rockall AG. Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically
    Indeterminate Adnexal Masses. JAMA Netw Open. 2020 Jan 3;3(1):e1919896. doi: 10.1001/jamanetworkopen.2019.19896. PubMed PMID: 31977064; PubMed Central PMCID: PMC6991280.
  11. Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419-423. doi:10.1097/IGC.0b013e3182070f17
  12. Kim H-J, Lee S-Y, Shin YR, Park CS, Kim K. The Value of Diffusion-Weighted Imaging in the Differential Diagnosis of Ovarian Lesions: A Meta-Analysis. Cao C, ed. PLoS One. 2016;11(2):e0149465. doi:10.1371/journal.pone.0149465
  13. Lindgren A, Anttila M, Rautiainen S, et al. Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI. Eur Radiol. 2017;27(9):4002-4012. doi:10.1007/s00330-017-4786-z
  14. Kyriazi S, Collins DJ, Messiou C, et al. Metastatic Ovarian and Primary Peritoneal Cancer: Assessing Chemotherapy Response with Diffusion-weighted MR Imaging—Value of Histogram Analysis of Apparent Diffusion Coefficients. Radiology. 2011;261(1):182-192. doi:10.1148/radiol.11110577
  15. Sala E, Kataoka MY, Priest AN, et al. Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. Radiology. 2012;263(1):149-159. doi:10.1148/radiol.11110175
  16. Rizzo S, Botta F, Raimondi S, et al. Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. Eur Radiol. May 2018. doi:10.1007/s00330-018-5389-z

Become A Member Today!

You will have access to a wide range of benefits that can help you advance your career and stay up-to-date with the latest developments in the field of radiology. These benefits include access to educational resources, networking opportunities with other professionals in the field, opportunities to participate in research projects and clinical trials, and access to the latest technologies and techniques. 

Check out our different membership options.

If you don’t find a fitting membership send us an email here.

①

Membership

for radiologists, radiology residents, professionals of allied sciences (including radiographers/radiological technologists, nuclear medicine physicians, medical physicists, and data scientists) & professionals of allied sciences in training residing within the boundaries of Europe

  • Reduced registration fees for ECR 1
  • Reduced fees for the European School of Radiology (ESOR) 2
  • Exclusive option to participate in the European Diploma. 3
  • Free electronic access to the journal European Radiology 4
  • Content e-mails for all ESR journals
  • Updates on offers & events through our newsletters
  • Exclusive access to the ESR feed in Juisci

€ 11 /year

Yes! That is less than €1 per month.
②

Free membership

for radiologists, radiology residents or professionals of allied sciences engaged in practice, teaching or research residing outside Europe as well as individual qualified professionals with an interest in radiology and medical imaging who do not fulfil individual or all requirements for any other ESR membership category & former full members who have retired from all clinical practice
  • Reduced registration fees for ECR 1
  • Free electronic access to the journal European Radiology
  • Content e-mails for all 3 ESR journals 4
  • Updates on offers & events through our newsletters
  • Exclusive access to the ESR feed in Juisci

€ 0

The best things in life are free.
③

ESR Friends

For students, company representatives or hospital managers etc.

  • Content e-mails for all 3 ESR journals 4
  • Updates on offers & events through our newsletters

€ 0

Friendship doesn’t cost a thing.
Apply now

The membership type best fitting for you will be selected automatically during the application process.

Footnotes:

01

Reduced registration fees for ECR 2024:
Provided that ESR 2023 membership is activated and approved by August 31, 2023.

Reduced registration fees for ECR 2025:
Provided that ESR 2024 membership is activated and approved by August 31, 2024.

02
Not all activities included
03
Examination based on the ESR European Training Curriculum (radiologists or radiology residents).
04
European Radiology, Insights into Imaging, European Radiology Experimental.